newsfilter
← Latest News
Business Wire·

Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

Safety aspects of AL001 development may qualify for (505)(b)(2) pathway for FDA approval Alzamend's recently completed a Phase IIA Study of AL001 in Alzheimer's and healthy patients that identified a candidate dose